Opioid Use Disorder (OUD) remains a significant public health crisis, with buprenorphine emerging as a key medication in its treatment. Approved by the FDA, buprenorphine works as a partial opioid agonist, helping reduce opioid use and improve treatment retention rates compared to placebo. Despite its effectiveness, challenges in patient retention and optimal treatment duration persist. …
Suboxone is a semisynthetic drug manufactured by Reckitt Benckiser pharmaceuticals for the treatment of opioid dependence. It was introduced to the market in October 2002 and gained popularity as a result of its efficacy and reduced potential for abuse compared to other opioid replacement agents such as methadone. The drug is comprised of the ingredients …
There are many new medications that have been engineered specifically for the treatment of opioid dependence. Those dependent on opioids tend to experience debilitating physical and psychological withdrawal symptoms upon discontinuation. To help individuals discontinue illicit opioids like heroin, an “opioid replacement therapy” drug is often prescribed. Two of the most common opioid replacement therapy …
Subutex and Suboxone are drugs that were approved by the FDA in 2002 for the treatment of opioid dependence. Both drugs contain the active ingredient buprenorphine, a semisynthetic opioid that acts as primarily as a partial mu-opioid receptor agonist. Buprenorphine also acts as an antagonist at the kappa and delta opioid receptors. Buprenorphine’s mechanism of …